Repetitive administration of tetrabenazine induces irreversible changes in locomotion and morphology of the substantia nigra in rats

Experimental and Toxicologic Pathology

Volumn 53, Issue 4, 2001, Pages 303-308

  Satou, Takao ^a   Anderson, Aileen J ^b   Itoh, Tatsuki ^a   Tamai, Yoshihisa ^a   Hayashi, Yoshiyuki ^a   Hashimoto, Shigeo ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Behavior; Dopamine; Locomotion; Mid brain; Monoamine; Morphometry; Parkinson s disease; Substantia nigra pars compacta; Tetrabenazine

Indexed keywords

DOPAMINE; GLIAL FIBRILLARY ACIDIC PROTEIN; MONOAMINE; TETRABENAZINE;

ADOLESCENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CELL COUNT; CELL SIZE; CONTROLLED STUDY; DOPAMINE METABOLISM; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MALE; MORPHOMETRICS; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; RAT; SUBSTANTIA NIGRA;

ANIMALIA;

EID: 0034808890     PISSN: 09402993     EISSN: None     Source Type: Journal    
DOI: 10.1078/0940-2993-00195     Document Type: Article

References (24)

1. Effects of nerve growth factor on dihydrotetrabenazine binding to PC12 cells
2. Recent developments in Parkinson’s disease and Huntington’s chorea
3. Hydroxyl radical production in the substantia nigra after 6-hydroxydopamine and hypoxia-reoxygenation
4. Effect of tetrabenazine on extrapyramidal movement disorders
5. Reserpineand tetrabenazine-sensitive transport of (3)H-histamine by the neuronal isoform of the vesicular monoamine transporter
6. Long-term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents
7. The oxidant stress hypothesis in Parkinson’s disease: Evidence supporting it
8. Dynamic storage of dopamine in rat brain synaptic vesicles in vitro
9. Altered brain metabolism of iron as a cause of neurodegenerative diseases?
10. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro
11. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias
12. The pharmacology of 1-phenyl-2-propylamino-pentane (PPAP), a deprenylderived new spectrum psychostimulant
13. (-)Deprenyl and (-)1phenyl-2-propylaminopentane, [(-)PPAP], act primarily as potent stimulants of action potential-transmitter release coupling in the catecholaminergic neurons
14. (-)1-(Benzofuran-2yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain
15. Genetic toxicity of dopamine
16. Drug-induced parkinsonism: A review
17. A radical hypothesis for neurodegeneration
18. Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain
19. TJS-010, a new prescription of Kampo medicine with putative antidepressive and anxiolytic properties; A behavioral study using experimental models for depression and anxiety
20. TJS-010, a new prescription of oriental medicine, antagonizes tetrabenazine-induced suppression of spontaneous locomotor activity in rats
21. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds
22. Levodopa/dopamine analogs as inhibitors of DNA synthesis in human melanoma cells
23. Effects of tricyclic antidepressants on tetrabenazine-induced depletion of brain monoamines in rats. 1. Norepinephrine